Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P19623

UPID:
SPEE_HUMAN

ALTERNATIVE NAMES:
Putrescine aminopropyltransferase

ALTERNATIVE UPACC:
P19623; B1AKP9; Q15511

BACKGROUND:
Spermidine synthase, identified by its alternative name Putrescine aminopropyltransferase, is integral to the biosynthesis of spermidine from putrescine and dcSAM. It exhibits a pronounced preference for putrescine, playing a vital role in the polyamine pathway, which is essential for cellular stability and regeneration.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Spermidine synthase opens avenues for novel therapeutic interventions. Given its central role in the polyamine pathway, critical for cell viability and growth, targeting this enzyme could offer new strategies in treating diseases characterized by abnormal cell proliferation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.